Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ISX:SDPC's EV-to-EBITDA is ranked better than 56.12% of 98
companies
in the Medical Distribution industry
Industry Median: 8.61
vs ISX:SDPC: 7.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PT Millennium Pharmacon International Tbk (ISX:SDPC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Millennium Pharmacon International Tbk's PE Ratio (TTM) for today is calculated as:
PT Millennium Pharmacon International Tbk's share price for today is Rp181.00.
PT Millennium Pharmacon International Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp30.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk EV-to-EBITDA Chart
PT Millennium Pharmacon International Tbk Annual Data
ISX:SDPC vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, PT Millennium Pharmacon International Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Millennium Pharmacon International Tbk EV-to-EBITDA vs Medical Distribution Industry
PT Millennium Pharmacon International Tbk's current Enterprise Value is Rp1,040,261 Mil.
PT Millennium Pharmacon International Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp133,690 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a EV-to-EBITDA of 7.78 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Millennium Pharmacon International Tbk. This is near median its historical median of 7.92. Over the past decade, PT Millennium Pharmacon International Tbk's EV-to-EBITDA has ranged from 6.58 to 11.35. According to the industry distribution chart, PT Millennium Pharmacon International Tbk ranks #43 out of 98 companies in the Medical Distribution industry, placing it in the top 43.9%.
Is PT Millennium Pharmacon International Tbk's EV-to-EBITDA too high?
PT Millennium Pharmacon International Tbk's current EV-to-EBITDA of 7.78 is near median its 10-year median of 7.92. Over the past 10 years, this metric has ranged from a low of 6.58 to a high of 11.35. The Medical Distribution industry median EV-to-EBITDA is 8.61. PT Millennium Pharmacon International Tbk's value of 7.78 is 9.6% below this industry median. Based on the distribution chart, PT Millennium Pharmacon International Tbk ranks #43 out of 98 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Millennium Pharmacon International Tbk ranks #43 out of 98 companies for EV-to-EBITDA. This puts PT Millennium Pharmacon International Tbk in the upper half of its industry. The industry median EV-to-EBITDA is 8.61. PT Millennium Pharmacon International Tbk's value of 7.78 is 9.6% below this benchmark. Historically, PT Millennium Pharmacon International Tbk's own EV-to-EBITDA has ranged from 6.58 to 11.35 over the past decade. While the company's 10-year median is 7.92 vs. the industry median of 8.61, PT Millennium Pharmacon International Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.61, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Millennium Pharmacon International Tbk's current EV-to-EBITDA of 7.78 is 9.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Millennium Pharmacon International Tbk. For the Medical Distribution industry, the median EV-to-EBITDA is 8.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Millennium Pharmacon International Tbk's current EV-to-EBITDA is 7.78, which is near median its own 10-year median of 7.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Fairly Valued. The stock's GF Value™ is Rp166.83, compared to a current price of Rp181.00 — trading 8.5% above its estimated fair value. The current EV-to-EBITDA is 7.78, which is near median its 10-year median of 7.92 and 9.6% below the Medical Distribution industry median of 8.61. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current EV-to-EBITDA is 7.78 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp181.00 is trading 8.5% above its estimated GF Value™ of Rp166.83.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Fairly Valued.
Key valuation signals for ISX:SDPC:
EV-to-EBITDA: 7.78 (near median its 10-year median of 7.92)
GF Value™: Rp166.83 vs. price of Rp181.00 (8.5% above fair value)
Industry Position: 9.6% below the Medical Distribution median (#43 of 98)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score
Get the complete analysis for ISX:SDPC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
